Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020781 | 0.88 | PDE2A (0.41) | KIF11DPP4DPP7MAOB | |
| SCHEMBL20791064 | 0.88 | PDE2A (0.41) | KIF11DPP4DPP7MAOB | |
| SCHEMBL20790946 | 0.88 | PDE2A (0.41) | KIF11DPP4DPP7MAOB | |
| Hydrochloric Acid SCHEMBL27160016 | 0.86 | HTR2C (0.41) | KIF11DPP4DPP7MAOB | |
| Hydrochloric Acid SCHEMBL27204338 | 0.86 | HTR2C (0.41) | KIF11DPP4DPP7MAOB | |
| SCHEMBL10199934 | 0.78 | TRPV3 (0.44) | MAOB | |
| SCHEMBL20811548 | 0.76 | MAOA (0.37) | KIF11MAOB | |
| SCHEMBL20811547 | 0.76 | MAOA (0.37) | KIF11MAOB | |
| Hydrochloric Acid SCHEMBL22206747 | 0.75 | MAOA (0.36) | KIF11MAOB | |
| Hydrochloric Acid SCHEMBL22206746 | 0.75 | MAOA (0.36) | KIF11MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266861-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056834-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094338-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8933104-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140329862-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809342-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2655331-A1 | GLUCAGON RECEPTOR MODULATORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085745-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120165343-A1 | Glucagon Receptor Modulators | PFIZER INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329862-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | KIF11 4048/4885DPP4 151/4885DPP8 891/4885 |
| US-20150094338-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | KIF11 4048/4885DPP4 151/4885DPP8 891/4885 |
| US-20120165343-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | KIF11 4048/4885DPP4 151/4885DPP8 891/4885 |
| US-20150266861-A1 | Glucagon Receptor Modulators | GLP1R, GCGR, GPR119 | KIF11 4048/4885DPP4 151/4885DPP8 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.